Quris Technologies
Tel Aviv, Israel· Est.
AI‑driven organ‑on‑a‑chip platform that predicts human drug safety to accelerate development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $28M
AI Company Overview
AI‑driven organ‑on‑a‑chip platform that predicts human drug safety to accelerate development.
Technology Platform
A patented Bio‑AI Clinical Prediction Platform that integrates high‑throughput Patients‑on‑a‑Chip assays with continuous machine‑learning model training to predict human drug safety and efficacy.
Opportunities
Scaling the platform across multiple therapeutic areas and securing licensing deals with large pharma could generate recurring revenue and reduce drug development costs.
Risk Factors
Technical scalability of organ‑chip manufacturing and regulatory acceptance of AI‑derived safety predictions pose significant execution risks.
Competitive Landscape
Quris differentiates itself from pure in‑silico AI firms by integrating real‑world organ‑chip data, but must compete with other AI‑biology platforms that are also advancing predictive pre‑clinical models.